Jon Congleton - 21 Nov 2025 Form 4 Insider Report for Mineralys Therapeutics, Inc. (MLYS)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: MLYS
Reported as of: 21 Nov 2025
Net transaction value: +$13,004
SEC form: 4
Accepted by SEC: 24 Nov 2025, 17:07:17 UTC
Prior SEC filing: 13 Nov 2025
Next SEC filing: 13 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Adam Levy, Attorney-in-fact

Key filing fact

Jon Congleton filed Form 4 for Mineralys Therapeutics, Inc. (MLYS) on 24 Nov 2025.

Key facts

This page summarizes Jon Congleton's Form 4 filing for Mineralys Therapeutics, Inc. (MLYS).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 24 Nov 2025, 17:07.

Change

Previous filing in this sequence was filed on 13 Nov 2025.
Current net transaction value: +$13,004.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001644975 Primary reporting owner

Congleton Jon

Relationship: Chief Executive Officer, Director
Address: 150 N. RADNOR CHESTER ROAD,, SUITE F200, RADNOR
Signature: /s/ Adam Levy, Attorney-in-fact
Signature date: 24 Nov 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MLYS transaction

Common Stock

Options Exercise

Transaction value: $13,004
Shares: +24,082
Change %: +3.8%
Price: $0.5400
Shares after: 655,387
Date: 21 Nov 2025
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MLYS transaction Derivative

Stock Option

Options Exercise

Transaction value: $0
Shares: -24,082
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 21 Nov 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 24,082
Exercise price: $0.5400
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Due to a rounding error, the exercise price for this stock option was originally reported as $0.53 per share on the Reporting Person's Form 3 filed on February 9, 2023.

Footnote F2

The stock option vested with respect to 25% of the underlying shares on March 12, 2022 and the remaining shares in 36 substantially equal monthly installments thereafter.